{
    "id": 26076,
    "fullName": "ETV6 - FGFR4",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-FGFR4 results from the fusion of ETV6 (also referred to as TEL) and FGFR4 (PMID: 24124571), and demonstrates constitutive kinase activity and the ability to transform cells in culture (PMID: 24124571).",
            "references": [
                {
                    "id": 88,
                    "pubMedId": 24124571,
                    "title": "Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124571"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - FGFR4",
    "createDate": "02/20/2017",
    "updateDate": "02/20/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2264,
                "geneSymbol": "FGFR4",
                "terms": [
                    "FGFR4",
                    "CD334",
                    "JTK2",
                    "TKF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 10010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 27224,
                "profileName": "ETV6 - FGFR4"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 V550E in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34267,
                "profileName": "ETV6 - FGFR4 FGFR4 V550E"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 V550E demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34267,
                "profileName": "ETV6 - FGFR4 FGFR4 V550E"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19606,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 C552F in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34268,
                "profileName": "ETV6 - FGFR4 FGFR4 C552F"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 C552F demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34268,
                "profileName": "ETV6 - FGFR4 FGFR4 C552F"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 C552W demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34269,
                "profileName": "ETV6 - FGFR4 FGFR4 C552W"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19608,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 C552Y in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34270,
                "profileName": "ETV6 - FGFR4 FGFR4 C552Y"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 C552Y demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34270,
                "profileName": "ETV6 - FGFR4 FGFR4 C552Y"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19594,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 V548L demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34271,
                "profileName": "ETV6 - FGFR4 FGFR4 V548L"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19595,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 V548M demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34272,
                "profileName": "ETV6 - FGFR4 FGFR4 V548M"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 A553P demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34273,
                "profileName": "ETV6 - FGFR4 FGFR4 A553P"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ETV6-FGFR4 and FGFR4 A553V demonstrated resistance to treatment with Fisogatinib (BLU-554) in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34274,
                "profileName": "ETV6 - FGFR4 FGFR4 A553V"
            },
            "therapy": {
                "id": 3165,
                "therapyName": "BLU-554",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19604,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 V550L in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34278,
                "profileName": "ETV6 - FGFR4 FGFR4 V550L"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19605,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 V550M in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34279,
                "profileName": "ETV6 - FGFR4 FGFR4 V550M"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2874455 treatment inhibited proliferation of cells co-expressing ETV6-FGFR4 and FGFR4 C552R in culture (PMID: 31575540).",
            "molecularProfile": {
                "id": 34280,
                "profileName": "ETV6 - FGFR4 FGFR4 C552R"
            },
            "therapy": {
                "id": 2032,
                "therapyName": "LY2874455",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17083,
                    "pubMedId": 31575540,
                    "title": "Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31575540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27224,
            "profileName": "ETV6 - FGFR4",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34267,
            "profileName": "ETV6 - FGFR4 FGFR4 V550E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34268,
            "profileName": "ETV6 - FGFR4 FGFR4 C552F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34269,
            "profileName": "ETV6 - FGFR4 FGFR4 C552W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34270,
            "profileName": "ETV6 - FGFR4 FGFR4 C552Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34271,
            "profileName": "ETV6 - FGFR4 FGFR4 V548L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34272,
            "profileName": "ETV6 - FGFR4 FGFR4 V548M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34273,
            "profileName": "ETV6 - FGFR4 FGFR4 A553P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34274,
            "profileName": "ETV6 - FGFR4 FGFR4 A553V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34278,
            "profileName": "ETV6 - FGFR4 FGFR4 V550L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34279,
            "profileName": "ETV6 - FGFR4 FGFR4 V550M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34280,
            "profileName": "ETV6 - FGFR4 FGFR4 C552R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}